

**Contents**

Chapter 1 Thinking about medicine	852
Chapter 2 History and examination	853
Chapter 3 Cardiovascular medicine	853
Chapter 4 Chest medicine	856
Chapter 5 Endocrinology	858
Chapter 6 Gastroenterology	858
Chapter 7 Renal medicine	859
Chapter 8 Haematology	859
Chapter 9 Infectious diseases	859
Chapter 10 Neurology	860
Chapter 11 Oncology and palliative care	860
Chapter 12 Rheumatology	861
Chapter 13 Surgery	863
Chapter 14 Clinical chemistry	864
Chapter 15 Eponymous syndromes	864
Chapter 16 Radiology	867
Chapter 17 Reference intervals	867
Chapter 18 Practical procedures	867
Chapter 19 Emergencies	867

**Chapter 1: Thinking about medicine**

- 1 Davis K, Stremikis K, Squires D, *et al*. *Mirror, mirror on the wall: How the performance of the US healthcare system compares internationally*. New York: The Commonwealth Fund, 2014. <http://www.commonwealthfund.org/publications/fund-reports/2014/jun/mirror-mirror>
- 2 Appleby J. *Spending on health and social care over the next 50 years. Why think long term?* London: The Kings Fund, 2013. <https://www.kingsfund.org.uk/time-to-think-differently/publications/spending-health-and-social-care-over-next-50-years>
- 3 Begley A, Pritchard-Jones K, Biriot V M, *et al*. Listening to patients with cancer: using a literary-based research method to understand patient-focused care. *BMJ Open* 2014; 4(10):e005550. <http://bmjopen.bmj.com/content/4/10/e005550>
- 4 Francis R. *Report of the Mid-Staffordshire NHS Foundation Trust Public Enquiry*. London: The Stationery Office, 2013. <http://webarchive.nationalarchives.gov.uk/20150407084003/http://www.midstaffpublicenquiry.com/home>
- 5 Saunders J. Compassion. *Clin Med* 2015; 15:121-4. <http://www.clinmed.rcpjjournal.org/content/15/2/121.full.pdf+html>
- 6 Mani N, Slevin N, Hudson A. What three wise men have to say about diagnosis. *BMJ* 2011; 343:e7769. <http://www.bmj.com/content/343/bmj.d7769>
- 7 Klein JG. Five pitfalls in decisions about diagnosis and prescribing. *BMJ* 2005; 330:781-4. <http://www.bmj.com/content/330/7494/781>
- 8 Schulz K. *Being wrong: Adventures in the margin of error*. London: Portobello Books, 2011
- 9 Berlinger N. *After harm: Medical error and the ethics of forgiveness*. Baltimore, MD: John Hopkins University Press, 2005
- 10 Little P, White P, Kelly J, *et al*. Randomised control trial of a brief intervention targeting predominantly non-verbal communication in general practice consultations. *Br J Gen Pract* 2015; 65(635):e351-6. <http://bjgp.org/content/65/635/e351.long>
- 11 Heath I. A wolf in sheep's clothing: a critical look at the ethics of drug taking. *BMJ* 2003; 327:856. <http://www.bmj.com/content/327/7419/856>
- 12 Eley D, Wilkinson D, Cloninger CR. Physician understand thyself, and develop your resilience. *BMJ Careers* 2013; 18 April. <http://careers.bmj.com/careers/advice/view-article.html?id=20011843>
- 13 Academy of Royal Colleges. *A code of practice for the diagnosis and confirmation of death*. 2010. <http://www.aomrc.org.uk/publications/reports-guidance/ukdec-reports-and-guidance/code-practice-diagnosis-confirmation-death/>
- 14 Steinhauser KE, Christakis NA, Clipp EC, *et al*. Factors considered important at the end of life by patients, family, physicians, and other care providers. *JAMA* 2000; 284(19):2476-82. <http://jamanetwork.com/journals/jama/fullarticle/193279>
- 15 Ruegger J, Hodgkinson S, Field-Smith A, *et al*. Care of adults in the last days of life: summary of NICE guidance. *BMJ* 2015; 351:h6631. <http://www.bmj.com/content/351/bmj.h6631>
- 16 Sokol DK. *Doing clinical ethics: A hands on guide for clinicians and others*. Amsterdam: Springer Netherlands, 2012
- 17 Sokol DK, McFadzean WA, Dickson WA, *et al*. Ethical dilemmas in the acute setting: a frame-work for clinicians. *BMJ* 2011; 343:d5528. <http://www.bmj.com/content/343/bmj.d5528.long>



- 18 Huxtable R. For and against the four principles of biomedical ethics. *Clin Ethics* 2013; 8(2/3):39-43
- 19 NICE. *Depression: The treatment and management of depression in adults* [CG90]. 2009, updated 2016. <https://www.nice.org.uk/guidance/CG90>
- 20 NICE. *Violence and aggression: Short-term management in mental health, health and community setting* [NG10]. 2015. <https://www.nice.org.uk/guidance/ng10>
- 21 O'Mahony D, O'Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. *Age Ageing* 2015; 44(2):213-8. <https://academic.oup.com/ageing/article-lookup/doi/10.1093/ageing/afu145>
- 22 Kurrle SE, Cameron ID, Geeves RB. A quick ward assessment of older patients by junior doctors. *BMJ* 2014; 350:h607. <http://www.bmj.com/content/350/bmj.h607>
- 23 NICE. *Falls in older people: Assessing risk and prevention* [CG161]. 2013. <https://www.nice.org.uk/guidance/cg161>
- 24 Knight M, Tuffnell D, Kenyon S, et al. (eds) on behalf of MBRRACE-UK. *Saving lives, improving mothers' care: surveillance of maternal deaths in the UK 2012-2014 and lessons learned to inform maternity care from the UK and Ireland. Confidential Enquiries into Maternal Deaths and Morbidity 2009-2014*. Oxford: National Perinatal Epidemiology Unit, University of Oxford, 2016
- 25 Greenhalgh T. *How to read a paper* (5th edn). Oxford: Blackwell Books, 2014
- 26 Greenland S, Senn SJ, Rothman KJ, et al. Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. *Eur J Epidemiol* 2016; 31:337-50
- 27 Greenhalgh T, Howick J, Maskrey N. Evidence based medicine: a movement in crisis? *BMJ* 2014; 348:g3725. <http://www.bmj.com/content/348/bmj.g3725>

## Chapter 2: History and examination

- 1 Spence D. The world is round. *BMJ* 2008; 336:1134
- 2 Magliner D. Localized cervical pruritus as the presenting symptom of a spinal cord tumor. *Pediatr Emerg Care* 2006; 22(10):746-7
- 3 Mackowiak PA, Wasserman SS, Levine MM. A critical appraisal of 98.6 degrees F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich. *JAMA* 1992; 268(12):1578-80. <http://jamanetwork.com/journals/jama/article-abstract/400116>
- 4 Roghmann MC, Warner J, Mackowiak PA. The relationship between age and fever magnitude. *Am J Med Sci* 2001; 322(2):68-90. <http://www.sciencedirect.com/science/article/pii/S0002962915346103>
- 5 Diskin CJ. Towards an understanding of oedema. *BMJ* 1999; 318:1610. <http://bmj.com/cgi/content/full/318/7198/1610>
- 6 Cheung W, Yu PX, Little BM, et al. Anorexia and cachexia in renal failure—is leptin the culprit? Role of leptin and melanocortin signaling in uremia-associated cachexia. *J Am Soc Nephrol* 2005; 16:2245-50. <http://www.jci.org/articles/view/22521>
- 7 Rastogi V, Purohit P, Peters BP, et al. Pulmonary infection with *Serratia marcescens*. *Indian J Med Microbiol* 2002; 20:167-8. <http://www.ijmm.org/text.asp?2002/20/3/167/6946>
- 8 Koumbourlis AC. Pectus excavatum: pathophysiology and clinical characteristics. *Paediatr Respir Rev* 2009; 10(1):3-6. [http://www.prrjournal.com/article/S1526-0542\(08\)00083-3/abstract](http://www.prrjournal.com/article/S1526-0542(08)00083-3/abstract)
- 9 Anglin R, Yuan Y, Moayyedi P, et al. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. *Am J Gastroenterol* 2014; 109:811-19. <http://www.nature.com/ajg/journal/v109/n6/full/ajg201482a.html>
- 10 NICE. *Depression: The treatment and management of depression in adults* [CG90]. 2009, updated 2016. <http://www.nice.org.uk/CG90>
- 11 Ford AC, Marwaha A, Lim A, et al. What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2010; 8(10):830-7. <http://www.ncbi.nlm.nih.gov/pubmed?term=20541625>
- 12 Hodgkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. *Age and Ageing* 2012; 41 Suppl 3:iii35-40. [http://ageing.oxfordjournals.org/content/41/suppl\\_3/iii35.long](http://ageing.oxfordjournals.org/content/41/suppl_3/iii35.long)
- 13 NICE guidelines: Chest pain of recent onset: assessment and diagnosis. Updated Nov 2016. <https://www.nice.org.uk/guidance/cg95/chapter/Recommendations#people-presenting-with-stable-chest-pain>
- 14 Moore C. A functional neuroimaging study of the variables that generate category-specific object processing differences. *Brain* 1999; 122 (Pt 5):943-62. <http://brain.oxfordjournals.org/content/122/5/943.long>
- 15 Assié G, Bahurel H, Bertherat J, et al. The Nelson's syndrome... revisited. *Pituitary* 2004; 7:209-15. <http://link.springer.com/article/10.1007/s11102-005-1403-y>
- 16 Dickinson CJ, Martin JF. Megakaryocytes and platelet clumps as the cause of finger clubbing. *Lancet* 1987; 2(8573):1434-5. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(87\)91132-9/abstract](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(87)91132-9/abstract)

## Chapter 3: Cardiovascular medicine

- 1 Britton J. Bupropion: a new treatment for smokers. *BMJ* 2000; 321:65. <http://www.bmj.com/cgi/content/full/321/7253/65>
- 2 Hippisley-Cox J. Predicting cardiovascular risk in England and Wales. *BMJ* 2008; 336:1475. <http://www.bmj.com/content/336/7659/1475>
- 3 Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. *CMAJ* 2008; 178(5):576-84. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2244680/>
- 4 Capewell S. "Chest pain—please admit": is there an alternative? *BMJ* 2000; 320:951. <http://www.bmj.com/cgi/content/full/320/7240/951>
- 5 Berk W. Clinical implications of low QRS complex voltage. *J Emerg Med* 1987; 5:305-10
- 6 Herzog C, Zwerner PL, Doll JR, et al. Significant coronary artery stenosis: comparison on per-patient and per-vessel or per-segment basis at 64-section CT angiography. *Radiology* 2007; 244(1):112-20. <http://radiology.rsna.org/content/244/1/112.short>
- 7 Aspirin for primary prevention of disease. [http://www.nyrtdc.nhs.uk/docs/dud/DU\\_65\\_Aspirin.pdf](http://www.nyrtdc.nhs.uk/docs/dud/DU_65_Aspirin.pdf)
- 8 NICE. *Unstable angina and NSTEMI: Early management* [CG94]. 2010, updated 2013. <https://www.nice.org.uk/guidance/cg94>



- 9 Nattel S, Opie LH. Controversies in atrial fibrillation. *Lancet* 2006; 367:262. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(06\)68037-9/abstract](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(06)68037-9/abstract)
- 10 Behr ER, Veysey MJ, Berry D, et al. Optimum dose of digoxin. *Lancet* 1997; 349(9068):1845 [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(05\)61735-7/fulltext](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)61735-7/fulltext)
- 11 The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. *N Engl J Med* 1997; 336:525-33. <http://www.nejm.org/doi/full/10.1056/NEJM199702203360801>
- 12 NICE. General principles for treating people with stable angina. In *Stable angina: Management* [CG126]. Chapter 13. 2011, updated 2016. <https://www.nice.org.uk/guidance/cg126/chapter/1-Guidance#general-principles-for-treating-people-with-stable-angina>
- 13 NICE. *Chest pain of recent onset: Assessment and diagnosis* [CG95]. 2010, updated 2016. <http://www.nice.org.uk/guidance/CG95>
- 14 Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J* 2016; 37(3):267-355. <http://eurheartj.oxfordjournals.org/content/37/3/267.long>
- 15 Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J* 2012; 33(20):2569-619. <http://eurheartj.oxfordjournals.org/content/33/20/2569.long>
- 16 Junghans C. Risk assessment after acute coronary syndrome. *BMJ* 2006; 333:1080. <http://www.bmj.com/content/333/7578/1079>
- 17 Lichtman JH, Bigger JT, Blumenthal JA, et al. Depression and Coronary Heart Disease: Recommendations for Screening, Referral, and Treatment: A Science Advisory From the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Psychiatric Association. *Circulation* 2008; 118:1768-75. <http://circ.ahajournals.org/content/118/17/1768.long>
- 18 DVLA. *Cardiovascular disorders: Assessing fitness to drive*. March 2016. <https://www.gov.uk/guidance/cardiovascular-disorders-assessing-fitness-to-drive>
- 19 Gorenek B, Lundqvist C, Terradellas J, et al. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. *Eur Heart J Acute Cardiovasc Care* 2015; 4(4):388-97
- 20 Matteson EL, Kluge FJ. Think clearly, be sincere, act calmly: Adolf Kussmaul (February 22, 1822-May 20, 1902) and his relevance to medicine in the 21st century. *Curr Opin Rheumatol* 2003; 15(1):29-34
- 21 Massimo M. Minimally invasive coronary surgery: fad or future? *BMJ* 1998; 316:88
- 22 NICE. *Off-pump coronary artery bypass grafting* [IPG377]. 2011. <http://guidance.nice.org.uk/IPG377>
- 23 Brown WR, Moody DM, Venkata R, Challa VR, et al. Longer duration of cardiopulmonary bypass is associated with greater numbers of cerebral microemboli. *Stroke* 2000; 31:707-13. <http://stroke.ahajournals.org/content/31/3/707>
- 24 Perez-Silva A, Merino J. Frequent ventricular extrasystoles: significance, prognosis and treatment. *ESC E-J Cardiol Pract* 2011; 9(17). <http://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-9/Frequent-ventricular-extrasystoles-significance-prognosis-and-treatment>
- 25 NICE. *Atrial fibrillation: Management*. 2014. <https://www.nice.org.uk/guidance/cg180/chapter/2-Recommendations>
- 26 Lubitz SA, Magnani JW, Ellinor PT, et al. Atrial fibrillation and death after myocardial infarction: risk marker or causal mediator? *Circulation* 2011; 123:2063-5. <http://circ.ahajournals.org/content/123/19/2063.abstract>
- 27 Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. *N Engl J Med* 2002; 347:1825-33. <http://www.nejm.org/doi/full/10.1056/NEJMoa021328>
- 28 Oral H. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. *N Engl J Med* 2006; 354(9):934-41. <http://www.nejm.org/doi/full/10.1056/NEJMoa050955>
- 29 Phang R, Prutkin J, Ganz L. Overview of atrial flutter. *UpToDate*®. 2015. [http://www.uptodate.com/contents/overview-of-atrial-flutter?source=search\\_result&search=atrial+flutter&selectedTitle=1-150](http://www.uptodate.com/contents/overview-of-atrial-flutter?source=search_result&search=atrial+flutter&selectedTitle=1-150)
- 30 Mant J. Warfarin vs aspirin for stroke prevention in elderly with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. *Lancet* 2007; 370:493-503. <http://www.thelancet.com/journals/lancet/article/PIIS0140673607612331/abstract>
- 31 Bristow M, Saxon L, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. *N Engl J Med* 2004; 350(21):2140-50. <http://www.nejm.org/doi/full/10.1056/NEJMoa032423>
- 32 NICE. *Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure* [TA314]. 2014. <https://www.nice.org.uk/guidance/ta314>
- 33 NICE. *Chronic heart failure* [CG108]. 2010. <https://www.nice.org.uk/guidance/cg108>
- 34 Patient. *Palliative care of heart failure*. 2016. <http://www.patient.co.uk/showdoc/40024526/>
- 35 McKee PA, Castelli WP, McNamara PM, et al. The natural history of congestive heart failure: the Framingham study. *N Engl J Med* 1971; 285(26):1441-6. <http://www.nejm.org/doi/full/10.1056/NEJM197112232852601>
- 36 Dargie HJ, McMurray JJ. Diagnosis and management of heart failure. *BMJ* 1994; 308:321-8. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2539274/>
- 37 Levenson JW, McCarthy EP, Lynn J, et al. The last six months of life for patients with congestive heart failure. *J Am Geriatr Soc* 2000; 48(5 Suppl):S101-9. <http://onlinelibrary.wiley.com/doi/10.1111/j.1532-5415.2000.tb03119.x/abstract>
- 38 Cleland JG, McGowan J, Clark A, et al. The evidence for beta blockers in heart failure. *BMJ* 1999; 319:524-5. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1115260/>
- 39 Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. *J Am Coll Cardiol* 2008; 52(3):190-9
- 40 Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. *N Engl J Med* 1999; 341:709-17. <http://content.nejm.org/cgi/reprint/341/10/709.pdf>
- 41 Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. *N Engl J Med* 2004; 351(20):2049-57. <http://content.nejm.org/cgi/content/full/351/20/2049>



- 42 Stewart S, McMurray JJ. Palliative care for heart failure. Time to move beyond treating and curing to improving the end of life. *BMJ* 2002; 325(7370):915-16. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1124429/>
- 43 Addington-Hall J. Dying from heart failure: lessons from palliative care. *BMJ* 1998; 317(7164):961-2. <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1114039>
- 44 NICE. *Hypertension in adults: Diagnosis and management* [CG127]. 2011, updated 2016. <https://www.nice.org.uk/guidance/cg127>
- 45 MacMahon S, Alderman MH, Lindholm LH, et al. Blood-pressure-related disease is a global health priority. *Lancet* 2008; 371:1480-2. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(08\)60632-7/fulltext](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)60632-7/fulltext)
- 46 Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* 2003; 361(9362):1060-13. <http://www.ncbi.nlm.nih.gov/pubmed/12493255>
- 47 Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. *N Engl J Med* 2008; 58:1887-98. <http://content.nejm.org/cgi/reprint/358/18/1887.pdf>
- 48 Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventative strategy. *Health Technol Assess* 2003; 7(31):1-94. <https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0015113/>
- 49 SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med* 2015; 373(22):2103-16
- 50 ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. *JAMA* 2002; 288:2981-97. <http://jama.ama-assn.org/content/288/23/2981.full>
- 51 van den Meiracker AH, Dees A. Hypertensive crisis: definition, pathophysiology and treatment. *Ned Tijdschr Geneesk* 1999; 143(44):2185-90
- 52 Stollerman GH. Rheumatic carditis. *Lancet* 1995; 346:390-2
- 53 Albert D, Harel L, Karrison T. The treatment of rheumatic carditis: a review and meta-analysis. *Medicine* 1995; 74:1-12
- 54 Koudy Williams J, Vita JA, Manuck SB, et al. Psychosocial factors impair vascular responses of coronary arteries. *Circulation* 1991; 84:2146-53
- 55 Steptoe A, Mollloy GJ. Personality and heart disease. *Heart* 2007; 93:783-4
- 56 Huffman JC, Celano CM, Beach SR, et al. Depression and cardiac disease: epidemiology, mechanisms, and diagnosis. *Cardiovasc Psychiatry Neurol* 2013; 2013:695925. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3638710/>
- 57 Otto C. Aortic stenosis--listen to the patient, look at the valve. *N Engl J Med* 2000; 343:652-4. <http://www.nejm.org/doi/full/10.1056/NEJM200008313430910>
- 58 Chopra HL, Nanda N. *Textbook of Cardiology (A Clinical & Historical Perspective)*. New Delhi: Jaypee Brothers Medical Publishers, 2012; 667
- 59 Soutter H. The repair of mitral stenosis. *Br Med J* 1925; 2(3379):603-6
- 60 Ogur G. Variable clinical expression of Holt-Oram syndrome in three generations. *Turk J Pediatr* 1998; 40(4):613-18. <https://www.ncbi.nlm.nih.gov/labs/articles/10028874/>
- 61 British Heart Foundation. *Inflammation and your heart: Endocarditis, pericarditis and myocarditis*. 2015. <https://www.bhf.org.uk/publications/heart-conditions/medical-information-sheets/inflammation-and-your-heart>
- 62 Chambers J, Sandoe J, Ray S, et al. The infective endocarditis team: recommendations from an international working group. *Heart* 2014; 100(7):524-7. <http://heart.bmj.com/content/100/7/524.long>
- 63 Durack D, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. *Am J Med* 1994; 96: 200-9.
- 64 Beeching N. *Infectious Diseases*. London: Wolfe, 1994; 136.
- 65 NICE. *Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures* [CG64]. 2008, updated 2016. <https://www.nice.org.uk/Search?q=CG64>
- 66 Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis. *Eur Heart J* 2015; 36(44):3075-128. <http://eurheartj.oxfordjournals.org/content/36/44/3075.long>
- 67 Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur Heart J* 2013; 34:2636-48. <http://eurheartj.oxfordjournals.org/content/34/33/2636.long>
- 68 Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases. *BMJ* 2002; 325(7370):915-16. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1124429/>
- 69 Baumgartner H, Bonhoeffer P, De Groot NM, et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). *Eur Heart J* 2010; 31(23):2915-57. <http://eurheartj.oxfordjournals.org/content/31/23/2915.long>
- 70 De Mozzi P, Longo UG, Galanti G, et al. Bicuspid aortic valve: a literature review and its impact on sport activity. *Br Med Bull* 2008; 85:63-85. <http://bmb.oxfordjournals.org/content/85/1/63.long>
- 71 NICE. *Transcatheter endovascular closure of perimembranous ventricular septal defect* [IPG336]. 2010. <https://www.nice.org.uk/guidance/IPG336>
- 72 Bashore TM. Adult congenital heart disease: right ventricular outflow tract lesions. *Circulation* 2007; 115(14):1933-47. <http://circ.ahajournals.org/content/115/14/1933.long>
- 73 Wang XM, Wu LB, Sun C, et al. Clinical application of 64-slice spiral CT in the diagnosis of the Tetralogy of Fallot. *Eur J Radiol* 2007; 64(2):296-301. [http://www.ejradiology.com/article/S0720-048X\(07\)00103-9/abstract](http://www.ejradiology.com/article/S0720-048X(07)00103-9/abstract)
- 74 Driver and Vehicle Licensing Agency. *Assessing fitness to drive - a guide for medical professionals*. 2016. <https://www.gov.uk/government/publications/assessing-fitness-to-drive-a-guide-for-medical-professionals>



- 1 Johnson DC. Importance of adjusting carbon monoxide diffusing capacity (DLCO) and carbon monoxide transfer coefficient (KCO) for alveolar volume. *Respir Med* 2000; 94(1):28-37. [http://www.resmedjournal.com/article/S0954-6111\(99\)90740-0/abstract](http://www.resmedjournal.com/article/S0954-6111(99)90740-0/abstract)
- 2 Spira A. Airway gene expression; a novel diagnostic test for lung cancer in smokers. *Proc Amer Assoc Cancer Res* 2006; 47:242
- 3 Doerschuk C. Pulmonary alveolar proteinosis - is host defense awry? *N Engl J Med* 2007; 356: 547-9. <http://www.nejm.org/doi/full/10.1056/NEJMp068259>
- 4 NICE. *Pneumonia in adults: Diagnosis and management* [CG191]. 2014. <https://www.nice.org.uk/guidance/cg191>
- 5 Man SY, Lee N, Ip M, *et al.* Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong. *Thorax* 2007 62:348-53. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2092476/>
- 6 Lim WS. Severity assessment in community-acquired pneumonia: moving on. *Thorax* 2007; 62:287-8. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2092475/>
- 7 Kumar S, Hammerschlag MR. Acute respiratory infection due to *Chlamydia pneumoniae*: current status of diagnostic methods. *Clin Infect Dis* 2007; 44(4):568-76. <http://cid.oxfordjournals.org/content/44/4/568.long>
- 8 Stringer JR, Beard CB, Miller RF, *et al.* A new name for *Pneumocystis* from humans and new perspectives on the host-pathogen relationship. *Emerg Infect Dis* 2002; 8(9):891-6.
- 9 Kaplan JE, Benson C, Holmes KT, *et al.* *Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents*. Atlanta, GA: CDC, 2009. <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5804a1.htm>
- 10 Hui DS. Review of clinical symptoms and spectrum in humans with influenza A/H5N1 infection. *Respirology* 2008; 13 Suppl 1:S10-3. <http://www.ncbi.nlm.nih.gov/pubmed/18366521>
- 11 The Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian Influenza A (H5N1) Infection in Humans. *N Engl J Med* 2005; 353:1374-85. <http://content.nejm.org/cgi/content/full/353/13/1374>
- 12 Engin A. Influenza type A (H5N1) virus infection. *Mikrobiyol Bul* 2007; 41(3):485-94. <http://www.ncbi.nlm.nih.gov/pubmed/17933264>
- 13 Public Health England. *Avian influenza: guidance and algorithms for managing human cases*. 2014. <https://www.gov.uk/government/publications/avian-influenza-guidance-and-algorithms-for-managing-human-cases>
- 14 *Avian influenza guidance and algorithms*. [http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb\\_C/1195733851442](http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1195733851442)
- 15 British Thoracic Society. *Guidelines on severe acute respiratory syndrome*. 2004. <http://www.brit-thoracic.org.uk/guidelines/severe-acute-respiratory-syndrome-guideline.aspx>
- 16 Hui DS. An overview on severe acute respiratory syndrome (SARS). *Monaldi Arch Chest Dis* 2005; 63(3):149-57
- 17 Gumel AB, Nuño M, Chowell G. Mathematical assessment of Canada's pandemic influenza preparedness plan. *Can J Infect Dis Med Microbiol* 2008; 19(2):185-92. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605860/>
- 18 Pasteur MC, Bilton D, Hill AT, *et al.* British Thoracic Society guideline for non-CF bronchiectasis. *Thorax* 2010; 65 Suppl 1:i1-58. [http://thorax.bmj.com/content/65/Suppl\\_1/i1.long](http://thorax.bmj.com/content/65/Suppl_1/i1.long)
- 19 Ramsey BW, Davies J, McElvaney NG, *et al.* A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. *N Engl J Med* 2011; 365(18):1663-72. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3230303/>
- 20 Rehman A, Baloch NU, Janahi IA. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. *N Engl J Med* 2015; 373(18):1783-4. <http://www.nejm.org/doi/pdf/10.1056/NEJMc1510466>
- 21 Alton EW, Armstrong DK, Ashby D, *et al.* Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. *Lancet Respir Med* 2015; 3(9):684-91. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673100/>
- 22 NICE. *Guidance on the diagnosis and treatment of lung cancer*. 2011. <http://guidance.nice.org.uk/CG121>
- 23 Bertazzi PA. Descriptive epidemiology of malignant mesothelioma. *Med Lav* 2005; 96(4):287-303. <http://www.ncbi.nlm.nih.gov/pubmed/16457426>
- 24 Tsiouris A, Walesby RK. Malignant pleural mesothelioma: current concepts in treatment. *Nat Clin Pract Oncol* 2007; 4(6):344-52. <http://www.nature.com/nrclinonc/journal/v4/n6/full/ncponc0839.html>
- 25 NICE. *Lung cancer: Diagnosis and management* [CG121]. 2011. <http://guidance.nice.org.uk/CG121>
- 26 Agarwal R. Allergic bronchopulmonary aspergillosis. *Chest* 2009; 135:805-26. <http://www.sciencedirect.com/science/article/pii/S0012369209602099>
- 27 Graf K. Five-years surveillance of invasive aspergillosis in a university hospital. *BMC Infect Dis* 2011; 11:163. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128051/>
- 28 Herbrecht R, Denning DW, Patterson TF, *et al.* Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. *N Engl J Med* 2002; 347:408-15. <http://www.nejm.org/doi/full/10.1056/NEJMoa020191>
- 29 Morfín-Maciél B, Barragán-Meijueiro Mde L, Nava-Ocampo AA. Individual and family household smoking habits as risk factors for wheezing among adolescents. *Prev Med* 2006; 43(2):98-100. <http://www.sciencedirect.com/science/article/pii/S0091743506001538>
- 30 Størdal K, Johannesdottir GB, Bentsen BS, *et al.* Acid suppression does not change respiratory symptoms in children with asthma and gastro-oesophageal reflux disease. *Arch Dis Child* 2005; 90(9):956-60. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1720585/>
- 31 Douglas JD. If you want to cure their asthma, ask about their job. *Prim Care Respir J* 2005; 14(2):65-71. <http://www.nature.com/articles/pcrj2004122>
- 32 Holloway EA, West RJ. Integrated breathing and relaxation training (the Papworth Method) for adults with asthma in primary care: a randomised controlled trial. *Thorax* 2007; 62(12):1039-42. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2094294/>



- 33 British Thoracic Society. *British guideline on the management of asthma*. 2016. <https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2016/>
- 34 Cates CJ, Cates MJ, Lasserson TJ. Regular treatment with formoterol for chronic asthma: serious adverse events. *Cochrane Database Syst Rev* 2008; 4:CD006923. <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006923.pub2/abstract>
- 35 Anon. Using beta 2-stimulants in asthma. *Drug Ther Bull* 1997; 35:1-4.
- 36 NICE. *Omalizumab for severe persistent allergic asthma* [TA133]. 2007. <https://www.nice.org.uk/guidance/TA133>
- 37 Hensley MJ. Use of inhaled corticosteroids was associated with the development of cataracts. *Evid Based Med* 1998; 3:24. <http://ebm.bmj.com/content/3/1/24.full.pdf+html>
- 38 Anon. Beyond the lungs—a new view of COPD. *Lancet* 2007; 370:713. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(07\)61349-X/abstract](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)61349-X/abstract)
- 39 Wouters E. COPD: a chronic and overlooked pulmonary disease. *Lancet* 2007; 370:715-16. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(07\)61352-X/abstract](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)61352-X/abstract)
- 40 Steiner M, Barton RL, Singh SJ, et al. Nutritional enhancement of exercise performance in chronic obstructive pulmonary disease: a randomised controlled trial. *Thorax* 2003; 58(9):745-51. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1746806/>
- 41 Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2006; 3:CD001287. <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001287.pub2/abstract>
- 42 Soriano JB, Lamprecht B, Ramírez AS, et al. Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. *Lancet Respir Med* 2015; 3(6):443-50. [http://www.thelancet.com/journals/lanres/article/PIIS2213-2600\(15\)00157-5/abstract](http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(15)00157-5/abstract)
- 43 Tiotropium versus salmeterol for the prevention of exacerbations of COPD. *N Engl J Med* 2011; 364:1093-103. <http://www.nejm.org/doi/full/10.1056/NEJMoa1008378>
- 44 Nannini L, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus separate components for COPD. *Cochrane Database Syst Rev* 2007; 4:CD003794. <http://www.ncbi.nlm.nih.gov/pubmed/17943798>
- 45 Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. *Am J Respir Crit Care Med* 1994; 149(3 Pt 1):818-24. <http://www.atsjournals.org/doi/pdf/10.1164/ajrccm.149.3.7509706>
- 46 Diaz-Reganon Valverde G, Fernández Rico R, Iribarren Sarrías JL, et al. The administration of 20 ppm of inhaled nitric oxide produces a faster response than the inhalation of 5 ppm in adult respiratory distress syndrome. *Rev Esp Anesthesiol Reanim* 2000; 47(2):57-62
- 47 Afshari A, Brok J, Møller AM, et al. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) and acute lung injury in children and adults. *Cochrane Database Syst Rev* 2010; 7:CD002787. <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002787.pub2/abstract>
- 48 Lamontagne F, Briel M, Guyatt GH, et al. Corticosteroid therapy for acute lung injury, acute respiratory distress syndrome, and severe pneumonia: a meta-analysis of randomized controlled trials. *J Crit Care* 2010; 25(3):420-35. [http://www.jccjournal.org/article/S0883-9441\(09\)00234-2/abstract](http://www.jccjournal.org/article/S0883-9441(09)00234-2/abstract)
- 49 Deal EN, Hollands JM, Schramm GE, et al. Role of corticosteroids in the management of acute respiratory distress syndrome. *Clin Ther* 2008; 30(5):787-99. <http://www.sciencedirect.com/science/article/pii/S0149291808001823>
- 50 Davies C, Gleeson FV, Davies RJ, et al. BTS guidelines for the management of pleural infection. *Thorax* 2003; 58 Suppl 2:ii18-28. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766018/>
- 51 Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breathing and hypertension. *N Engl J Med* 2000; 342:1378-84. <http://www.nejm.org/doi/full/10.1056/NEJM200005113421901>
- 52 NICE. *Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome* [TA139]. 2008. <http://www.nice.org.uk/Guidance/TA139>
- 53 Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. *N Engl J Med* 2007; 357(21):2153-65. <http://www.nejm.org/doi/full/10.1056/NEJMra071714>
- 54 Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. *Thorax* 2008; 63(Suppl V):v1-v58. [http://thorax.bmj.com/content/63/Suppl\\_5/v1.long](http://thorax.bmj.com/content/63/Suppl_5/v1.long)
- 55 Grönhagen-Riska C. Angiotensin-converting enzyme. I. Activity and correlation with serum lysozyme in sarcoidosis, other chest or lymph node diseases and healthy persons. *Scand J Respir Dis* 1979; 60(2):83-93
- 56 Iannuzzi MC, Sah BP. Sarcoidosis. In: *Merk Manual*. [http://www.merckmanuals.com/professional/pulmonary\\_disorders/sarcoidosis/sarcoidosis.html](http://www.merckmanuals.com/professional/pulmonary_disorders/sarcoidosis/sarcoidosis.html)
- 57 Evans M, Sharma O, LaBree L, et al. Differences in clinical findings between Caucasians and African Americans with biopsy-proven sarcoidosis. *Ophthalmology* 2007; 114(2):325-33. [http://www.aaojournal.org/article/S0161-6420\(06\)00994-8/abstract](http://www.aaojournal.org/article/S0161-6420(06)00994-8/abstract)
- 58 Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. *Thorax* 2008; 63:v1-v58. [http://thorax.bmj.com/content/63/Suppl\\_5/v1.long](http://thorax.bmj.com/content/63/Suppl_5/v1.long)
- 59 Watanabe N, Tanada S, Sasaki Y. Pulmonary clearance of aerosolized 99mTc-DTPA in sarcoidosis I patients. *Q J Nucl Med Mol Imaging* 2007; 51(1):82-90. <http://www.minervamedica.it/en/journals/nuclear-med-molecular-imaging/issue.php?cod=R39Y9999N00>
- 60 Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. *Thorax* 2008; 63(Suppl V):v1-v58. [http://thorax.bmj.com/content/63/Suppl\\_5/v1.long](http://thorax.bmj.com/content/63/Suppl_5/v1.long)
- 61 Fisher M, Nathan SD, Hill C, et al. Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis. *J Manag Care Spec Pharm* 2017; 23(3):S17-S24.



- 1 Simpson RW, Shaw JE, Zimmet PZ. The prevention of type 2 diabetes—lifestyle change or pharmacotherapy? A challenge for the 21st century. *Diabetes Res Clin Pract* 2003; 59(3):165–80. <http://www.ncbi.nlm.nih.gov/pubmed/12590013/>
- 2 Cartwright RD. The role of sleep in changing our minds: a psychologist's discussion of papers on memory reactivation and consolidation in sleep. *Learn Mem* 2004; 11(6):660–3. <https://www.ncbi.nlm.nih.gov/pubmed/15346993/>
- 3 Weetman AP. Autoimmune thyroid disease: propagation and progression. *Eur J Endocrinol* 2008; 148(1):1–9. <http://www.eje-online.org/content/148/1/1.long>
- 4 Gale E. Is there really an epidemic of type 2 diabetes? *Lancet* 2003; 362:503–4. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(03\)14148-7/abstract](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)14148-7/abstract)
- 5 Inoue K, Matsumoto M, Akimoto K. Fasting plasma glucose and HbA1c as risk factors for type 2 diabetes. *Diabet Med* 2008; 25(10):1157–63. <http://onlinelibrary.wiley.com/doi/10.1111/j.1464-5491.2008.02572.x/abstract>
- 6 Westman EC, Yancy WS Jr, Mavropoulos JC, et al. The effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index diet on glycemic control in type 2 diabetes mellitus. *Nutr Metab (Lond)* 2008; 5:36. <https://www.ncbi.nlm.nih.gov/pubmed/18633336/>
- 7 Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. *BMJ* 2011; 343:d6898. <https://www.ncbi.nlm.nih.gov/pubmed/21323424/>
- 8 Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med* 2015; 373(22):2117–28. <http://www.nejm.org/doi/full/10.1056/NEJMc1600827>
- 9 Dose Adjustment For Normal Eating (DAFNE). <http://www.dafne.uk.com/>
- 10 The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993; 329(14):977–86. <http://www.nejm.org/doi/full/10.1056/NEJM199309303291401>
- 11 Belch J. Aspirin does not help as primary prevention in DM. *BMJ* 2008; 337:a1840. [http://www.bmj.com/cgi/content/full/337/oct16\\_2/a1840](http://www.bmj.com/cgi/content/full/337/oct16_2/a1840)
- 12 Davidson MB, Wong A, Hamrahian AH, et al. Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors. *Endocr Pract* 2008; 14(8):985–92. <http://journals.aace.com/doi/abs/10.4158/EP.14.8.985>
- 13 NICE. *Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care* [CG73]. <https://www.nice.org.uk/guidance/cg73>
- 14 Murad MH, Coto-Yglesias F, Wang AT, et al. Clinical review: drug-induced hypoglycemia: a systematic review. *J Clin Endocrinol Metab* 2009; 94(3):741–5. <http://press.endocrine.org/doi/pdf/10.1210/jc.2008-1415>
- 15 Kapoor RR, James C, et al. Advances in the diagnosis and management of hyperinsulinemic hypoglycemia. *Nat Clin Pract Endocrinol Metab* 2009; 5(2):101–12. <http://www.nature.com/nrendo/journal/v5/n2/full/ncpendmet1046.html>
- 16 Geraghty M, Draman M, Moran D, et al. Hypoglycaemia in an adult male: a surprising finding in pursuit of insulinoma. *Surgeon* 2008; 6(1):57–60
- 17 Abraham P, Avenell A, Park CM, et al. A systematic review of drug therapy for Graves' hyperthyroidism. *Eur J Endocrinol* 2005; 153(4):489–98. <http://www.eje-online.org/content/153/4/489.long>
- 18 Kahaly GJ, Pitz S, Hommel G, et al. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. *J Clin Endocrinol Metab* 2005; 90(9):5234–40. <http://press.endocrine.org/doi/pdf/10.1210/jc.2005-0148>
- 19 Hedback G, Odén A. Recurrence of hyperparathyroidism; a long-term follow-up after surgery for primary hyperparathyroidism. *Eur J Endocrinol* 2003; 148(4):413–21. <http://www.eje-online.org/content/148/4/413.long>
- 20 Hoff AO, Cote GJ, Gagel RF. Multiple endocrine neoplasias. *Annu Rev Physiol* 2000; 62:377. <http://www.annualreviews.org/doi/pdf/10.1146/annurev.physiol.62.1.377>
- 21 Renehan AG, Brennan BM. Acromegaly, growth hormone and cancer risk. *Best Pract Res Clin Endocrinol Metab* 2008; 22(4):639–57. <http://pubmedhh.nlm.nih.gov/cgi-bin/abstract.cgi?id=18971124&from=pubmed>
- 22 Etxabe J, Vazquez JA. Morbidity and mortality in Cushing's disease: an epidemiological approach. *Clin Endocrinol* 1994; 40:479–84. <http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2265.1994.tb02486.x/abstract>
- 23 Brosnan CM, Gowing NF. Addison's disease. *BMJ* 1996; 312(7038):1085–7. <https://www.ncbi.nlm.nih.gov/pubmed/8850885/>
- 24 State Coroner for Western Australia. *Failure to diagnose: Addison's disease*. 2007. <http://www.racgp.org.au/afp/200710/200710bird.pdf>
- 25 Boyle JG, Davidson DF, Perry CG, et al. Comparison of diagnostic accuracy of urinary free metanephrines, vanillyl mandelic acid, and catecholamines and plasma catecholamines for diagnosis of pheochromocytoma. *J Clin Endocrinol Metab* 2007; 92(12):4602–8. <http://press.endocrine.org/doi/pdf/10.1210/jc.2005-2668>
- 26 Herrmann HC, Chang G, Klugherz BD, et al. Hemodynamic effects of sildenafil in men with severe coronary artery disease. *N Engl J Med* 2000; 342(22):1622–6. <http://www.nejm.org/doi/full/10.1056/NEJM200006013422201>
- 27 Minniti G, Gilbert DC, Brada M. Modern techniques for pituitary radiotherapy. *Rev Endocr Metab Disord* 2009; 10(2):135–44. <http://link.springer.com/article/10.1007%2F1154-008-9106-0>
- 28 Chanson P. Acromegaly. *Presse Med* 2009; 38(1):92–102. <https://www.ncbi.nlm.nih.gov/pubmed/19004622/>

## Chapter 6: Gastroenterology

- 1 Al Moutran H. Microstomia. *Medscape*. 2015. <http://www.emedicine.com/ent/topic148.htm>
- 2 Batur P, Stewart WJ, Isaacson JH. Increased prevalence of aortic stenosis in patients with arteriovenous malformations of the gastrointestinal tract in Heyde syndrome. *Arch Intern Med* 2003; 163(15):1382–4. <http://jamanetwork.com/journals/jamainternalmedicine/fullarticle/755859>
- 3 Unlugenc H, Guler T, Gunes Y, Isik G. Comparative study of the antiemetic efficacy of ondansetron, propofol and midazolam in the early postoperative period. *Eur J Anaesthesiol* 2004; 21(1):60–5. <http://pubmed.ncbi.nlm.nih.gov/cgi-bin/abstract.cgi?id=14768925&from=cqsr>



- 4 NICE. *Dyspepsia and gastro-oesophageal reflux disease* [CG184]. 2014. <https://www.nice.org.uk/Guidance/cg184>
- 5 NICE. *Acute upper gastrointestinal bleeding in over 16s: management* [CG141]. 2012. <https://www.nice.org.uk/Guidance/cg141>
- 6 NICE. *Suspected cancer: Recognition and referral* [NG12]. 2015. <https://www.nice.org.uk/Guidance/ng12>
- 7 European Crohn's and Colitis Organisation (ECCO). *ECCO Consensus on Surgery for Ulcerative Colitis*. 2016. <https://www.ecco-ibd.eu/index.php/publications/ecco-guidelines-science/published-ecco-guidelines.html>
- 8 European Crohn's and Colitis Organisation (ECCO). *ECCO Crohn's Disease (CD) Consensus Update (2016)*. 2016. <https://www.ecco-ibd.eu/index.php/publications/ecco-guidelines-science/published-ecco-guidelines.html>
- 9 Ludvigsson JF, Bai JC, Biagi F, *et al*. Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. *Gut* 63(8):1210-28. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112432/>
- 10 Juturi JV, Maghfoor I, Doll DC, *et al*. A case of biliary carcinoid presenting with pancreatitis and obstructive jaundice. *Am J Gastroenterol* 2000; 95(10):2973-4. <http://www.nature.com/ajg/journal/v95/n10/full/ajg20001463a.html>
- 11 Hillborn M, Pieninkeroinen I, Leone M. Seizures in alcohol-dependent patients: epidemiology, pathophysiology and management. *CNS Drugs* 2003; 17(14):1013-30. <https://www.ncbi.nlm.nih.gov/pubmed/14594442>
- 12 European Association for the Study of the Liver (EASL). *EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease*. *J Hepatol* 2016; 64(6):1388-402. [http://www.journal-of-hepatology.eu/article/S0168-8278\(15\)00734-5/fulltext](http://www.journal-of-hepatology.eu/article/S0168-8278(15)00734-5/fulltext)

## Chapter 7: Renal medicine

- 1 Scottish Intercollegiate Guidelines Network. *Management of suspected bacterial urinary tract infection in adults: a national clinical guideline* (SIGN 88). 2012. <http://www.sign.ac.uk/pdf/sign88.pdf>
- 2 Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. *Kidney Int Suppl* 2012; 2:1-138. <http://kdigo.org/home/guidelines/acute-kidney-injury/>
- 3 London AKI Network. *Guidelines and pathways*. <http://www.londonaki.net/clinical/guidelines-pathways.html>
- 4 NICE. *Algorithms for IV fluid therapy in adults*. 2013. <https://www.nice.org.uk/guidance/cg174/resources/intravenous-fluid-therapy-in-adults-in-hospital-algorithm-poster-set-191627821>
- 5 UK Renal Association. *Clinical practice guidelines: treatment of acute hyperkalaemia in adults*. March 2014. <http://www.renal.org/guidelines/joint-guidelines/treatment-of-acute-hyperkalaemia-in-adults#sthash.LACGYarj.dpbs>
- 6 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl* 2013; 3:1-150. <http://kdigo.org/home/guidelines/ckd-evaluation-management/>
- 7 Evans PD, Taal MW. Epidemiology and causes of chronic kidney disease. *Medicine* 2015; 43:450-3. [http://www.medicinenjournal.co.uk/article/S1357-3039\(15\)00117-6/fulltext](http://www.medicinenjournal.co.uk/article/S1357-3039(15)00117-6/fulltext)
- 8 NICE. *Chronic kidney disease in adults: Assessment and management* [CG182]. Updated Jan 2015. <https://www.nice.org.uk/guidance/cg182>
- 9 Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. *Kidney Int Suppl* 2012; 2:139-274. <http://kdigo.org/home/glomerulonephritis-gn/>
- 10 Molitch ME, Adler AI, Flyvbjerg A, *et al*. Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. *Kidney Int* 2015; 87(1):20-30. [http://www.kidney-international.theisn.org/article/S0085-2538\(15\)30004-1/abstract](http://www.kidney-international.theisn.org/article/S0085-2538(15)30004-1/abstract)

## Chapter 8: Haematology

- 1 van der Klooster JM. A medical mystery. Lead poisoning. *Singapore Med J* 2004; 45(10):497-9. <http://pubmedh.nlm.nih.gov/cgi-bin/abstract.cgi?id=15455173&from=cqsr>
- 2 The Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee. *Transfusion handbook* (5th edn). 2014. Available free at: <http://www.transfusion-guidelines.org/transfusion-handbook>
- 3 NICE. *Neutropenic sepsis: Prevention and management in people with cancer* [CG151]. 2012. <https://www.nice.org.uk/guidance/cg151>

## Chapter 9: Infectious diseases

- 1 Laxminarayan R, Duse A, Wattal C, *et al*. Antibiotic resistance - the need for global solutions. *Lancet Infect Dis* 2013; 13(12):1057-98. [http://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(13\)70318-9/abstract](http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(13)70318-9/abstract)
- 2 NICE. *Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use* [NG15]. 2015. <https://www.nice.org.uk/guidance/ng15>
- 3 NICE. *Tuberculosis* [NG33]. 2016. <https://www.nice.org.uk/guidance/ng33>
- 4 Public Health England. *PHE guidance on the use of antiviral agents for the treatment and prophylaxis of seasonal influenza*. 2016. [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/580509/PHE\\_guidance\\_antivirals\\_influenza\\_2016\\_2017.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/580509/PHE_guidance_antivirals_influenza_2016_2017.pdf)
- 5 Goldacre B. What the Tamiflu saga tells us about drug trials and big pharma. *The Guardian* 2014; 10 April. <https://www.theguardian.com/business/2014/apr/10/tamiflu-saga-drug-trials-big-pharma>
- 6 British Association for Sexual Health and HIV. *BASHH guidelines*. <https://www.bashh.org/guidelines> [accessed September 2016]



- 7 British HIV Association. *British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy* 2015. 2015. <http://www.bhiva.org/documents/Guidelines/Treatment/2015/2015-treatment-guidelines.pdf>
- 8 Loveday HP, Wilson JA, Pratt RJ, *et al.* epic3: National evidence based guidelines for preventing health-care-associated infections in NHS hospitals in England. *J Hosp Infect* 2014; 86(s1):s1-s70. [https://www.his.org.uk/files/3113/8693/4808/epic3\\_National\\_Evidence-Based\\_Guidelines\\_for\\_Preventing\\_HCAI\\_in\\_NHSE.pdf](https://www.his.org.uk/files/3113/8693/4808/epic3_National_Evidence-Based_Guidelines_for_Preventing_HCAI_in_NHSE.pdf)
- 9 Johnson V, Stockley JM, Dockrell D, *et al.* Fever in returned travellers presenting in the United Kingdom: recommendations for investigation and initial management. *J Infect* 2009; 59(1):1-18. <https://www.ncbi.nlm.nih.gov/pubmed/19595360>
- 10 Laloo DG, Shingadia D, Bell DJ. UK malaria treatment guidelines 2016. *J Infect* 2016; 72(6):635-49. [http://www.journalofinfection.com/article/S0163-4453\(16\)00047-5/abstract](http://www.journalofinfection.com/article/S0163-4453(16)00047-5/abstract)
- 11 Sinclair D, Donegan S, Iba R, *et al.* Artesunate versus quinine for severe malaria. *Cochrane Database Syst Rev* 2012; 6:CD005967. <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005967.pub4/full>
- 12 via World Health Organization. *Health topics*. <http://www.who.int/topics/en/> [accessed September 2016]
- 13 Rasmussen SA, Jamieson DJ, Honein MA, *et al.* Zika virus and birth defects — reviewing the evidence for causality. *N Engl J Med* 2016; 374:1981-7. <http://www.nejm.org/doi/full/10.1056/NEJMSr1604338#t=article>
- 14 Medlock JM, Leach SA. Effect of climate change on vector borne disease in the UK. *Lancet Infect Dis* 2015; 15(6):721-30. [http://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(15\)70091-5/abstract](http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(15)70091-5/abstract)
- 15 European concerted action on Lyme borreliosis (EUCALB). <http://www.eucalb.com> [accessed September 2016]
- 16 Sudarshi D, Brown M. Human African trypanosomiasis in non-endemic countries. *Clin Med* 2015; 15(1):70-3. <http://www.clinmed.rcpjournals.org/content/15/1/70.full.pdf>
- 17 Lambourne JR, Brooks T. Brucella and coxiella: if you don't look, you don't find. *Clin Med* 2015; 15(1):91-2. <http://www.clinmed.rcpjournals.org/content/15/1/91.abstract>
- 18 Forbes AE, Zochowski WJ, Dubrey SW, *et al.* Leptospirosis and Weil's disease in the UK. *QJM* 2012; 105(2):1151-62. <http://qjmed.oxfordjournals.org/content/105/12/1151.long>
- 19 World Health Organization. *Clinical management of patients with viral haemorrhagic fever: a pocket guide for front-line health workers: interim emergency guidance for country adaptation*. 2016. [http://apps.who.int/iris/bitstream/10665/205570/1/9789241549608\\_eng.pdf?ua=1](http://apps.who.int/iris/bitstream/10665/205570/1/9789241549608_eng.pdf?ua=1)
- 20 Barrett J, Brown M. Traveller's diarrhoea. *BMJ* 2016; 353:i1937. <http://www.bmj.com/content/353/bmj.i1937.long>
- 21 Riddle MS, DuPont HL, Connor BA. ACG clinical guideline: diagnosis, treatment, and prevention of acute diarrheal infections in adults. *Am J Gastroenterol* 2016; 111:602-22. doi:10.1038/ajg.2016.126. <http://glo.org/wp-content/uploads/2016/05/ajg2016126a.pdf>
- 22 Beeching N, Dassanayake A. Tropical liver disease. *Medicine* 2011; 39(9):556-60. [http://www.medicines-journal.co.uk/article/S1357-3039\(11\)00154-X/abstract](http://www.medicines-journal.co.uk/article/S1357-3039(11)00154-X/abstract)
- 23 Rodrigo C, Fernando D, Rajapakse S. Pharmacological management of tetanus: an evidence based review. *Crit Care* 2014; 18:217. <https://ccforum.biomedcentral.com/articles/10.1186/cc13797>
- 24 Varghese GM, Trowbridge P, Doherty T. Investigating and managing pyrexia of unknown origin. *BMJ* 2010; 341:c5470. <http://www.bmj.com/content/341/bmj.c5470.long>

## Chapter 10: Neurology

- 1 NICE. *Headaches in over 12s: Diagnosis and management* [CG150]. 2012. <https://www.nice.org.uk/guidance/cg150>
- 2 NICE. *Alteplase for treating acute ischaemic stroke* [TA264]. 2012. <https://www.nice.org.uk/guidance/ta264>
- 3 NICE. *Delirium: Prevention, diagnosis and management* [CG103]. 2010. <https://www.nice.org.uk/guidance/cg103>
- 4 Fong TG, Davis D, Growdon ME, *et al.* The interface between delirium and dementia in elderly adults. *Lancet Neurol* 2015; 14(8):823-32. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535349/>
- 5 NICE. *Dementia: Supporting people with dementia and their carers in health and social care* [CG42]. 2006, updated 2016. <https://www.nice.org.uk/guidance/cg42>
- 6 NICE. *Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease* [TA217]. 2011. <https://www.nice.org.uk/guidance/ta217>
- 7 Berg AT, Berkovic SF, Brodie MJ, *et al.* Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. *Epilepsia* 2010; 51(4):676-85. <https://www.ncbi.nlm.nih.gov/pubmed/20196795>
- 8 NICE. *Multiple sclerosis in adults: Management* [CG186]. 2014. <https://www.nice.org.uk/guidance/cg186>

## Chapter 11: Oncology and palliative care

- 1 Cancer Research. *UK statistics*. <http://www.cancerresearchuk.org/health-professional/cancer-statistics> [accessed September 2016]
- 2 National Cancer Institute. *Communication in cancer health: professional version*. [http://www.cancer.gov/about-cancer/coping/adjusting-to-cancer/communication-hp-pdq#section/\\_9](http://www.cancer.gov/about-cancer/coping/adjusting-to-cancer/communication-hp-pdq#section/_9)
- 3 Baile WF, Buckman R, Lenzi R, *et al.* SPIKES: a six-step protocol for delivering bad news: application to the patient with cancer. *Oncologist* 2000; 5(4):302-11. <http://theoncologist.alphamedpress.org/content/5/4/302.long>
- 4 National Cancer Institute. *The genetics of cancer*. 2015. <https://www.cancer.gov/about-cancer/causes-prevention/genetics/overview-pdq>
- 5 NICE. *Familial breast cancer: Classification, care and managing breast cancer and related risks in people with a family history of breast cancer* [CG164]. 2013, updated 2015. <https://www.nice.org.uk/guidance/cg164>
- 6 NICE. *Suspected cancer: Recognition and referral* [NG12]. 2015. <https://www.nice.org.uk/guidance/ng12>
- 7 Kerr DJ, Haller DG, Verweij J. Principles of chemotherapy. In Kerr DJ, Haller DG, van der Valde CJH, *et al.* (eds) *Oxford Textbook of Oncology* (3rd edn). Oxford: Oxford University Press; 2016:186-95



- 8 Pérez Fidalgo JA, García Fabregat L, Cervantes A, *et al.* Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. *Ann Oncol* 2012; 23(suppl 7): vii167-vii173. [https://academic.oup.com/annonc/article/23/suppl\\_7/vii167/145139/Management-of-chemotherapy-extravasation-ESMO-EONS](https://academic.oup.com/annonc/article/23/suppl_7/vii167/145139/Management-of-chemotherapy-extravasation-ESMO-EONS)
- 9 Loren AW, Mangu PB, Beck LN, *et al.* Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol* 2013; 31(19):2500-10. <http://ascopubs.org/doi/full/10.1200/JCO.2013.49.2678>
- 10 Ahmad SS, Duke S, Jena R, *et al.* Advances in radiotherapy. *BMJ* 2012; 345:e7765. <http://www.bmj.com/content/345/bmj.e7765.long>
- 11 DeAngelo D, Alyea EP. Oncologic emergencies. In: Singh AK, Loscalzo J (eds) *The Brigham Intensive Review of Internal Medicine*. Oxford: Oxford University Press, 2014:159-67
- 12 Lee DLY, Anthony A. Complications of systemic therapy - gut infections and acute diarrhoea. *Clin Med* 14(5):528-45. <http://www.clinmed.rcpjournals.org/content/14/5/528.full.pdf+html>
- 13 Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. *Mayo Clin Proc* 2010; 85(9):838-54. [http://www.mayoclinicproceedings.org/article/S0025-6196\(11\)60214-0/abstract](http://www.mayoclinicproceedings.org/article/S0025-6196(11)60214-0/abstract)
- 14 Sturgeon CM, Lai LC, Duffy MJ. Serum tumour markers: how to order and interpret them. *BMJ* 2009; 339:b3527. <http://www.bmj.com/content/339/bmj.b3527.long>
- 15 Schröder FH, Hugoson J, Roobol MJ, *et al.* Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow up. *Lancet* 2014; 384(9959):2027-35. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(14\)60525-0/abstract](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60525-0/abstract)
- 16 Temel JS, Greer JA, Muzikansky A, *et al.* Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med* 2010; 363:733-42. <http://www.nejm.org/doi/full/10.1056/NEJMoa1000678>
- 17 World Health Organization. *Analgesic ladder*. <http://www.who.int/cancer/palliative/painladder/en/>
- 18 NHS England. *NPSA safety alert: Risk of distress and death from inappropriate doses of naloxone in patients on long-term opioid/opiate treatment*. 2014. <https://www.england.nhs.uk/wp-content/uploads/2014/11/psa-inappropriate-doses-naloxone.pdf>
- 19 NHS Scotland. *Scottish palliative care guidelines*. 2014. <http://www.palliativecareguidelines.scot.nhs.uk/>
- 20 Universities of Hull, Staffordshire and Aberdeen. *Spiritual care at the end of life: A systematic review*. 2010. [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/215798/dh\\_123804.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/215798/dh_123804.pdf)
- 21 Kaye P. Spiritual pain. In: *Notes on symptom control in hospice and palliative care*. Hospice Education Institute. 1990.
- 22 Ruegger J, Hodgkinson S, Field-Smith A, *et al.* Care of adults in the last days of life. *BMJ* 2015; 351:h6631. <http://www.bmj.com/content/351/bmj.h6631>
- 23 General Medical Council. *Treatment and care towards the end of life*. 2010. [http://www.gmc-uk.org/static/documents/content/Treatment\\_and\\_care\\_towards\\_the\\_end\\_of\\_life\\_-\\_English\\_1015.pdf](http://www.gmc-uk.org/static/documents/content/Treatment_and_care_towards_the_end_of_life_-_English_1015.pdf)

## Chapter 12: Rheumatology

- 1 Doherty M, Dacre J, Dieppe P, *et al.* The 'GALS' locomotor screen. *Ann Rheum Dis* 1992; 51:1165-9. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1012427/>
- 2 Courtney P, Doherty M. Joint aspiration and injection. *Best Pract Res Clin Rheumatol* 2005; 19:345-69. [http://www.bprclinrheum.com/article/S1521-6942\(05\)00010-0/abstract](http://www.bprclinrheum.com/article/S1521-6942(05)00010-0/abstract)
- 3 Speed C. Low back pain. *BMJ* 2004; 328:1119-21. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC406328/>
- 4 NICE. *Low back pain in adults: Early management [CG88]*. 2009. <https://www.nice.org.uk/guidance/cg88>
- 5 Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. *Bull World Health Organ* 2003; 81(9):646-56. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2572542/>
- 6 Sowers M, Jannausch M, Stein E, *et al.* C-reactive protein as a biomarker of emergent osteoarthritis. *Osteoarthritis Cartilage* 2002; 10(8):595-601. <https://www.ncbi.nlm.nih.gov/pubmed/12479380>
- 7 NICE. *Osteoarthritis: Care and management [CG177]*. Available at: <https://www.nice.org.uk/guidance/cg177>
- 8 Bellamy N, Campbell J, Robinson V, *et al.* Viscosupplementation for the treatment of osteoarthritis of the knee. *Cochrane Database Syst Rev* 2006; 2:CD005321. <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005321.pub2/abstract>
- 9 García-De La Torre I. Advances in the management of septic arthritis. *Rheum Dis Clin North Am* 2003; 29(1):61-75. <https://www.ncbi.nlm.nih.gov/pubmed/12635500>
- 10 Ross JJ, Saltzman CL, Carling P, *et al.* Pneumococcal septic arthritis: review of 190 cases. *Clin Infect Dis* 2003; 36(3):319-27. <http://cid.oxfordjournals.org/content/36/3/319.long>
- 11 Coakley G, Mathews C, Field M, *et al.* BSR & BHPR, BOA, RCGP and BSAC guidelines for management of the hot swollen joint in adults, 2006. *Rheumatology (Oxford)* 2006; 45(8):1039-41. <http://rheumatology.oxfordjournals.org/content/45/8/1039.long>
- 12 Mathews CJ, Kingsley G, Field M, *et al.* Management of septic arthritis: a systematic review. *Ann Rheum Dis* 2007; 66(4):440-5. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1856038/>
- 13 Blizard Institute Clinical Effectiveness Group. *NSAIDs: Reducing the risk summary guidelines*. 2015. <http://www.blizard.qmul.ac.uk/ceg/resource-library/clinical-guidance/clinical-guidelines.html>
- 14 McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. *PLoS Med* 2011; 8(9):e1001098. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181230/>
- 15 Scarpignato C, Lanás A, Blandizzi C, *et al.* Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis - an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. International NSAID Consensus Group. *BMC Med* 2015; 13:55. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365808/>
- 16 Chan F, Wong VW, Suen BY, *et al.* Combination of COX-2 and PPI for prevention of recurrent ulcer bleeding in patients at very high risk. *Lancet* 2007; 369:1621-6. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(07\)60749-1/abstract](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)60749-1/abstract)
- 17 Calgüneri M, Ureten K, Akif Öztürk M, *et al.* Extra-articular manifestations of rheumatoid arthritis: results of a university hospital of 526 patients in Turkey. *Clin Exp Rheumatol* 2006; 24(3):305-8. <http://www.clinexprheumatol.org/article.asp?a=2873>



- 18 Young A, Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. *Best Pract Res Clin Rheumatol* 2007; 21(5):907-27. [http://www.bprclinrheum.com/article/S1521-6942\(07\)00065-0/abstract](http://www.bprclinrheum.com/article/S1521-6942(07)00065-0/abstract)
- 19 Farid SS, Azizi G, Mirshafiey A. Anti-citrullinated protein antibodies and their clinical utility in rheumatoid arthritis. *Int J Rheum Dis* 2013; 16(4):379-86. <http://onlinelibrary.wiley.com/doi/10.1111/1756-185X.12129/abstract>
- 20 Brown AK, Wakefield RJ, Conaghan PG, et al. New approaches to imaging early inflammatory arthritis. *Clin Exp Rheumatol* 2004; 22(5 Suppl 35): S18-25. <http://www.clinexprheumatol.org/article.asp?a=2432>
- 21 Szekanez Z, Kerekes G, Dér H, et al. Accelerated atherosclerosis in rheumatoid arthritis. *Ann N Y Acad Sci* 2007; 1108:349-58. <http://onlinelibrary.wiley.com/doi/10.1196/annals.1422.036/abstract>
- 22 Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum* 2010; 62(9):2569-81. <http://onlinelibrary.wiley.com/doi/10.1002/art.27584/abstract>
- 23 O'Dell JR. Therapeutic strategies for rheumatoid arthritis. *N Engl J Med* 2004; 350:2591-602. <http://www.nejm.org/doi/full/10.1056/NEJMra040226>
- 24 British Society for Rheumatology. *National guidelines for the monitoring of second line drugs*. 2000. [http://www.rheumatology.org.uk/includes/documents/cm\\_docs/2009/m/monitoring\\_second\\_line\\_drugs.pdf](http://www.rheumatology.org.uk/includes/documents/cm_docs/2009/m/monitoring_second_line_drugs.pdf)
- 25 NICE. *Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis [TA130]*. 2007. <https://www.nice.org.uk/guidance/ta130>
- 26 NICE. *Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor [TA195]*. 2010. <https://www.nice.org.uk/guidance/ta195>
- 27 NICE. *Tocilizumab for the treatment of rheumatoid arthritis [TA247]*. 2012. <https://www.nice.org.uk/guidance/ta247>
- 28 NICE. *Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs [TA234]*. 2011. <https://www.nice.org.uk/guidance/ta234>
- 29 Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. *Ann Rheum Dis* 2014; 73(3):529-35
- 30 Thompson A, Gandhi KK, Hochberg MC, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. *Arthritis Res Ther* 2015; 17(1):212. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536786/>
- 31 Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). *Ann Rheum Dis* 2006; 65(10):1301-11. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1798330/>
- 32 Sturrock R. Gout. Easy to misdiagnose. *BMJ* 2000; 320:132-3. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1128728/>
- 33 Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. *Rheumatology* 2007; 46(8):1372-4. <http://rheumatology.oxfordjournals.org/content/46/8/1372.full>
- 34 Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. *Arthritis Res Ther* 2006; 8 Suppl 1:S3. <https://arthritis-research.biomedcentral.com/articles/10.1186/ar1908>
- 35 Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. *N Engl J Med* 2005; 353(23):2450-61. <http://www.nejm.org/doi/full/10.1056/NEJMoa050373>
- 36 Zhang W, Doherty M, Bardin T, et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: Management. *Ann Rheum Dis* 2011; 70:571-5. <http://ard.bmj.com/content/70/4/571.full>
- 37 Wanders A, Heijde DV, Landewe R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. *Arthritis Rheum* 2012; 52(6):1756-65. <https://www.ncbi.nlm.nih.gov/pubmed/15934081>
- 38 NICE. *Adalimumab, etanercept and infliximab for ankylosing spondylitis [TA143]*. 2008. <https://www.nice.org.uk/guidance/ta143>
- 39 Hakim A, Clunie G, Haq I (eds). *Oxford handbook of rheumatology* (3rd edn). Oxford: Oxford University Press, 2011
- 40 Di Lorenzo AL. HLA-B27 syndromes. *Medscape*. 2015. <http://emedicine.medscape.com/article/1201027-overview>
- 41 Distler JH, Distler O. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies. *Ann Rheum Dis* 2010; 69 Suppl 1:i48-51. [http://ard.bmj.com/content/69/Suppl\\_1/i48.long](http://ard.bmj.com/content/69/Suppl_1/i48.long)
- 42 Gross WL, Reinhold-Keller E. [ANCA-associated vasculitis (Wegener's granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis). I. Systemic aspects, pathogenesis and clinical aspects.] *Z Rheumatol* 1995; 54(5):279-90. <https://www.ncbi.nlm.nih.gov/pubmed/8578884>
- 43 Rahman A. Systemic lupus erythematosus. *N Engl J Med* 2008; 358:929-39. <http://www.nejm.org/doi/full/10.1056/NEJMra071297>
- 44 NICE. *Final appraisal determination. Belimumab for treating active autoantibody-positive systemic lupus erythematosus*. 2016. <https://www.nice.org.uk/guidance/GID-TAG273/documents/final-appraisal-determination-document>
- 45 Goral S, Ynares C, Shappell SB, et al. Recurrent lupus nephritis in renal transplant recipients revisited: it is not rare. *Transplantation* 2003; 75(5):651-6. <https://www.ncbi.nlm.nih.gov/pubmed/12640304>
- 46 Baglin TP, Keeling DM, Watson HG. British Committee for Standards in Haematology. Guidelines on oral anticoagulation (warfarin): third edition - 2005 update. *Br J Haematol* 2006; 132(3):277-85. <https://www.ncbi.nlm.nih.gov/pubmed/16409292>
- 47 Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum* 2002; 44(8):2677-86. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3409311/>
- 48 Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum* 2012; 65(1):1-11
- 49 Trejo-Gutierrez JF, Larson JM, Abril A. Shortness of breath, weak pulses, and a high ESR. *Lancet* 2008; 371:176. [http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736\(08\)60109-9.pdf](http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(08)60109-9.pdf)



- 50 Dasgupta B, Borg FA, Hassan N, *et al*. BSR and BHPH guidelines for the management of GCA. *Rheumatology (Oxford)* 2010; 49(8):1594-7. <http://rheumatology.oxfordjournals.org/content/49/8/1594.long>
- 51 Dasgupta B, Giant Cell Arteritis Guideline Development Group. Concise guidance: diagnosis and management of giant cell arteritis. *Clin Med (Lond)* 2010; 10(4):381-6. <https://www.ncbi.nlm.nih.gov/pubmed/20849016>
- 52 Stephens RS, Brown C. Persistent lower abdominal and groin pain: what is the diagnosis? *Am J Med* 2005; 118(4):364-7. [http://www.amjmed.com/article/S0002-9343\(05\)00088-4/abstract](http://www.amjmed.com/article/S0002-9343(05)00088-4/abstract)
- 53 Weiner SM, Peter HH. Neuropsychiatric involvement in systemic lupus erythematosus. Part 1: clinical presentation and pathogenesis. *Med Klin* 2002; 97(12):730-7. <https://www.ncbi.nlm.nih.gov/pubmed/12491066>
- 54 Reilly PA, Littlejohn GO. Peripheral arthralgic presentation of fibrositis/fibromyalgia syndrome. *J Rheum* 1992; 19:281-3 <https://www.ncbi.nlm.nih.gov/pubmed/1629829>
- 55 Richards SC, Scott DL. Prescribed exercise in people with fibromyalgia: parallel group randomised controlled trial. *BMJ* 2002; 325:185-9. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC117444/>
- 56 Busch AJ, Schachter CL, Overend TJ, *et al*. Exercise for fibromyalgia: a systematic review. *J Rheumatol* 2008; 35:1130-44. <https://www.ncbi.nlm.nih.gov/pubmed/18464301>
- 57 Goldenberg DL. Multidisciplinary modalities in the treatment of fibromyalgia. *J Clin Psychiatry* 2008; 69 Suppl 2:25-9. <https://www.ncbi.nlm.nih.gov/pubmed/18537461>
- 58 NICE. *Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy): Diagnosis and management* [CG53]. 2007. <https://www.nice.org.uk/Guidance/cg53>
- 59 New Zealand Guidelines Group. *New Zealand acute low back pain guide*. 2004. [http://www.acc.co.nz/PRD\\_EXT\\_CSMP/groups/external\\_communications/documents/guide/prd\\_ctrbl12930.pdf](http://www.acc.co.nz/PRD_EXT_CSMP/groups/external_communications/documents/guide/prd_ctrbl12930.pdf)
- 60 Schneider M, Vernon H, Ko G, *et al*. Chiropractic management of fibromyalgia syndrome: a systematic review of the literature. *J Manipulative Physiol Ther* 2009; 32:25-40. <https://www.ncbi.nlm.nih.gov/pubmed/19121462>
- 61 Russell IJ, Orr MD, Littman B, *et al*. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. *Arthritis Rheum* 1994; 37:1593-601. <https://www.ncbi.nlm.nih.gov/pubmed/7526868>
- 62 Russell IJ, Vaeroy H, Javors M, *et al*. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. *Arthritis Rheum* 1992; 35:550-6. <https://www.ncbi.nlm.nih.gov/pubmed/1374252>
- 63 Wood PB, Schweinhardt P, Jaeger E, *et al*. Fibromyalgia patients show an abnormal dopamine response to pain. *Eur J Neurosci* 2007; 25:3576-82. <https://www.ncbi.nlm.nih.gov/pubmed/17610577>
- 64 Reichrath J, Bens G, Bonowitz A, *et al*. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. *J Am Acad Dermatol* 2005; 53(2):273-83. <https://www.ncbi.nlm.nih.gov/pubmed/16021123>

## Chapter 13: Surgery

- 1 American Society of Anesthesiologists Committee. Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration: application to healthy patients undergoing elective procedures: an updated report by the American Society of Anesthesiologists Committee on Standards and Practice Parameters. *Anesthesiology* 2011; 114(3):495-511. <https://www.ncbi.nlm.nih.gov/pubmed/21307770>
- 2 General Medical Council. *Consent: Patients and doctors making decisions together*. 2008. [http://www.gmc-uk.org/guidance/ethical\\_guidance/consent\\_guidance\\_index.asp](http://www.gmc-uk.org/guidance/ethical_guidance/consent_guidance_index.asp)
- 3 BAPEN. *Screening & 'MUST'*. 2016. <http://www.bapen.org.uk/screening-and-must/must>
- 4 NICE. *Anticoagulation—oral* [Clinical Knowledge Summaries]. 2015. <http://cks.nice.org.uk/anticoagulation-oral#!management>
- 5 NICE. *Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma* [TA268]. 2012. <https://www.nice.org.uk/guidance/ta268>
- 6 Hodi FS, O'Day SJ, McDermott DF, *et al*. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 2010; 363(8):711-23. <http://www.nejm.org/doi/full/10.1056/NEJMoa1003466>
- 7 NICE. *Early and locally advanced breast cancer: Diagnosis and treatment* [CG80]. 2009. <https://www.nice.org.uk/guidance/cg80>
- 8 NICE. *Advanced breast cancer: Diagnosis and treatment* [CG81]. 2009, updated 2014. <https://www.nice.org.uk/guidance/cg81>
- 9 NICE. *Obesity: Identification, assessment and management* [CG189]. 2014. <https://www.nice.org.uk/guidance/cg189>
- 10 Halpin V. Early cholecystectomy. *BMJ Best Practice*. <http://bestpractice.bmj.com/best-practice/evidence/intervention/0411/0/sr-0411-il.html>
- 11 NICE. *Varicose veins: Diagnosis and management* [CG168]. 2013. <https://www.nice.org.uk/guidance/cg168>

## Chapter 14: Clinical chemistry

- 1 NICE. *Intravenous fluid therapy in adults in hospital* [CG174]. 2013. <https://www.nice.org.uk/Guidance/cg174>
- 2 Levey A, Bosch JP, Lewis JB, *et al*. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med* 1999; 130:461-70. <https://www.ncbi.nlm.nih.gov/pubmed/10075613>
- 3 Renneboog B, Musch W, Vandemergel X, *et al*. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. *Am J Med* 2006; 119:7Le1-8. <https://www.ncbi.nlm.nih.gov/pubmed/16431193>
- 4 Robertson GL. Vaptan for the treatment of hyponatraemia. *Nat Rev Endocrinol* 2011; 7:151-61. <http://www.nature.com/nrendo/journal/v7/n3/full/nrendo.2010.229.html>
- 5 Smellie S. Spurious hypokalaemia. *BMJ* 2007; 334:693. <http://www.bmj.com/content/334/7595/693>
- 6 Thomas J, Doherty SM. HIV infection—a risk factor for osteoporosis. *J Acquir Immune Defic Syndr* 2003; 33(3):281-91. <https://www.ncbi.nlm.nih.gov/pubmed/12843738>



- 7 Patel AM, Goldfarb S. Got calcium? Welcome to the calcium-alkali syndrome. *J Am Soc Nephrol* 2002; 9:1440-3. <http://jasn.asnjournals.org/content/21/9/1440.long>
- 8 Berenson JR. Treatment of hypercalcemia of malignancy with bisphosphonates. *Semin Oncol* 2002; 29(Suppl 21):12-18. <https://www.ncbi.nlm.nih.gov/pubmed/12584690>
- 9 LeGrand SB, Leskuski D, Zama I. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. *Ann Intern Med* 2008; 149:259-63. <https://www.ncbi.nlm.nih.gov/pubmed/18711156>
- 10 Robey RB, Lash JP, Arruda JA. Does furosemide have a role in the management of hypercalcemia? *Ann Intern Med* 2009; 150:146-7. <https://www.ncbi.nlm.nih.gov/pubmed/19153420>
- 11 Fitzpatrick LA. The hypocalcemic states. In: Favus M (ed) *Disorders of bone and mineral metabolism*. Philadelphia, PA: Lippincott Williams & Wilkins, 2002:568-88
- 12 Kramer HJ, Choi HK, Atkinson K, et al. The association between gout and nephrolithiasis in men: The Health Professionals' Follow-Up Study. *Kidney Int* 2003; 64:1022-6. <https://www.ncbi.nlm.nih.gov/pubmed/12911552>
- 13 Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. *Osteoporos Int* 2008; 19:385-97. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2267485/>
- 14 NICE. *Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women* [TA160]. 2008, updated 2011. <https://www.nice.org.uk/Guidance/ta160>
- 15 Howe TE, Shea B, Dawson LJ, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. *Cochrane Database Syst Rev* 2011; 7:CD000333. <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000333.pub2/abstract>
- 16 Gillespie WJ. Hip protectors for preventing hip fractures in older people. *Cochrane Database Syst Rev* 2010; 10:CD001255. <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001255.pub4/abstract>
- 17 Eberling P. Osteoporosis in men. *N Engl J Med* 2008; 358:1474-82. <http://www.nejm.org/doi/full/10.1056/NEJMcp0707217>
- 18 Vollbrecht J, Rao DS. Tumor-induced osteomalacia. *N Engl J Med* 2008; 358:1282. <http://www.nejm.org/doi/full/10.1056/NEJMicm066066#t=article>
- 19 Wermers RA, Tiegs RD, Atkinson EJ, et al. Morbidity and mortality associated with Paget's disease of bone: a population study. *J Bone Miner Res* 2008; 23:819-25. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515478/>
- 20 NICE. *Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care* [CG73]. 2008. <https://www.nice.org.uk/guidance/cg73>
- 21 Anon. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994; 344:1383-9. <https://www.ncbi.nlm.nih.gov/pubmed/7968073>
- 22 Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. *N Engl J Med* 1995; 333:1301-8. <http://www.nejm.org/doi/full/10.1056/NEJM199511163332001#t=article>
- 23 Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med* 1996; 335:1001-9. <http://www.nejm.org/doi/full/10.1056/NEJM199610033351401#t=article>
- 24 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002; 360:7-22. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(02\)09327-3/abstract](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)09327-3/abstract)
- 25 Libby P. Inflammation in atherosclerosis. *Nature* 2002; 420:868-74. <http://www.nature.com/nature/journal/v420/n6917/full/nature01323.html>
- 26 Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. *BMJ* 2008; 337:a2423. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2583391/>
- 27 NICE. *Cardiovascular disease: Risk assessment and reduction, including lipid modification* [CG181]. 2014, updated 2016. <https://www.nice.org.uk/guidance/CG181>
- 28 McKenney JM, Davidson MH, Jacobson TA, et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. *Am J Cardiol* 2006; 8A:89C-94C. <https://www.ncbi.nlm.nih.gov/pubmed/16581336>
- 29 Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. *N Engl J Med* 2015; 372(16):1489-99. <http://www.nejm.org/doi/full/10.1056/NEJMoa1501030>

## Chapter 15: Eponymous syndromes

- 1 Todd J. The syndrome of Alice in Wonderland. *Can Med Assoc J* 1955; 73(9):701-4. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1826192/>
- 2 Cau C. The Alice in Wonderland syndrome. *Minerva Med* 1999; 90(10):397-401. <https://www.ncbi.nlm.nih.gov/pubmed/10767914>
- 3 Fritschy D, Fasel J, Imbert JC, et al. The popliteal cyst. *Knee Surg Sports Traumatol Arthrosc* 2006; 14(7):623-8. <https://www.ncbi.nlm.nih.gov/pubmed/16362357>
- 4 Scheinfeld NS. Erythema induratum (nodular vasculitis). *Medscape*. 2016. <http://emedicine.medscape.com/article/1083213-overview>
- 5 Hakim A, Gavin Clunie G, Haq I. Behçet's disease. In: *Oxford Handbook of Clinical Rheumatology* (3rd edn). Oxford: Oxford University Press, 2011:490-1.
- 6 Mariotti AJ, Agrawal R, Hotaling AJ. The role of tonsillectomy in pediatric IgA nephropathy. *Arch Otolaryngol Head Neck Surg* 2009; 135(1):85-7. <https://www.ncbi.nlm.nih.gov/pubmed/19153312>
- 7 Fourcade G, Bengler C, Campello CH, et al. [Bickerstaff's syndrome presenting with coma, tetraplegia and blindness]. *Rev Neurol (Paris)* 2007; 163(2):231-4. <https://www.ncbi.nlm.nih.gov/pubmed/17351542>
- 8 Fitzgerald RC, di Pietro M, Raganath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. *Gut* 2014; 63(1):7-42. <http://gut.bmj.com/content/63/1/7.long>
- 9 Tham T. *Guidelines on the diagnosis and management of Barrett's oesophagus - an update 2015*. [Online only] <http://www.bsg.org.uk/clinical-guidelines/oesophageal/guidelines-on-the-diagnosis-and-management-of-barrett-s-oesophagus.html>



- 10 Ambardekar AV, Krantz MJ. The Brugada syndrome: the perfect storm of genetics and environment? *Int J Cardiol* 2009; 141(1):108-9. <https://www.ncbi.nlm.nih.gov/pubmed/19157599>
- 11 Hedley PL, Jørgensen P, Schlamowitz S, et al. The genetic basis of Brugada syndrome: a mutation update. *Hum Mutat* 2009; 30(9):1256-66. <https://www.ncbi.nlm.nih.gov/pubmed/19606473>
- 12 Moon SJ, Lee JK, Kim TW, et al. Idiopathic transverse myelitis presenting as the Brown-Séquard syndrome. *Spinal Cord* 2008; 47(2):176-8. <http://www.nature.com/sc/journal/v47/n2/full/sc200823a.html>
- 13 Menon KV, Shah V, Kamath PS. The Budd-Chiari syndrome. *N Engl J Med* 2004; 350:578-85. <http://www.nejm.org/doi/full/10.1056/NEJMra020282>
- 14 Vaglio A, Moosig F, Zwerina J. Churg-Strauss syndrome: update on pathophysiology and treatment. *Curr Opin Rheumatol* 2012; 24(1):24-30. <https://www.ncbi.nlm.nih.gov/pubmed/22089097>
- 15 Liberski PP, Sikorska B, Hawu JJ, et al. Tubulovesicular structures are a consistent (and unexplained) finding in the brains of humans with prion diseases. *Virus Res* 2008; 132(1-2):226-8. <https://www.ncbi.nlm.nih.gov/pubmed/18164506>
- 16 CJD surveillance unit in Edinburgh. 2009. <http://www.cjd.ed.ac.uk/documents/figs.pdf>
- 17 Dorsey K, Zou S, Schonberger LB, et al. Lack of evidence of transfusion transmission of Creutzfeldt-Jakob disease in a US surveillance study. *Transfusion* 2009; 49(5):977-84. <https://www.ncbi.nlm.nih.gov/pubmed/19170987>
- 18 Iwasaki Y, Mimuro M, Yoshida M, et al. Clinical diagnosis of Creutzfeldt-Jakob disease: accuracy based on analysis of autopsy-confirmed cases. *J Neurol Sci* 2008; 277(1-2):119-23. <https://www.ncbi.nlm.nih.gov/pubmed/19056094>
- 19 Armstrong RA. Creutzfeldt-Jakob disease and vision. *Clin Exp Optom* 2006; 89(1):3-9. <https://www.ncbi.nlm.nih.gov/pubmed/16430434>
- 20 Zanusso G, Ferrari S, Cardone F, et al. Detection of pathologic prion protein in the olfactory epithelium in sporadic Creutzfeldt-Jakob disease. *N Engl J Med* 2003; 348:711-19. <http://www.nejm.org/doi/full/10.1056/NEJMoa022043#t=article>
- 21 Tattersall R, Turner B. Brown-Séquard and his syndrome. *Lancet* 2000; 356:61-3. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(00\)02441-7/abstract](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(00)02441-7/abstract)
- 22 Goodall CA, Head MW, Everington D, et al. Raised CSF phospho-tau concentrations in variant Creutzfeldt-Jakob disease: diagnostic and pathological implications. *J Neurol Neurosurg Psychiatry* 2006; 77(1):89-91. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2117383/>
- 23 Karazindiyanoglu S, Cayan S. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism. *Aging Male* 2008; 11(3):146-9. <https://www.ncbi.nlm.nih.gov/pubmed/18821291>
- 24 Studd J. A comparison of 19th century and current attitudes to female sexuality. *Gynecol Endocrinol* 2007; 23(12):673-81. <https://www.ncbi.nlm.nih.gov/pubmed/18075842>
- 25 Cussons AJ, Bhagat CI, Fletcher SJ, et al. Brown-Séquard revisited: a lesson from history on the placebo effect of androgen treatment. *Med J Aust* 2002; 177(11-12):678-9. <https://www.ncbi.nlm.nih.gov/pubmed/12463999>
- 26 Bliss M. *Harvey Cushing: A life in surgery*. Toronto: University of Toronto Press, 2005
- 27 Liberski PP, Brown P. Kuru: its ramifications after fifty years. *Exp Gerontol* 2009; 44(1-2):63-9. <https://www.ncbi.nlm.nih.gov/pubmed/18606515>
- 28 Miller N. *The misfolding diseases unfold*. Beremans Limited. 2004 [http://www.beremans.com/pdf/The\\_misfolding\\_diseases\\_unfold.pdf](http://www.beremans.com/pdf/The_misfolding_diseases_unfold.pdf)
- 29 Lepur D, Peterković V, Kalabrić-Lepur N. Neuromyelitis optica with CSF examination mimicking bacterial meningomyelitis. *Neurol Sci* 2009; 30(1):51-4. <https://www.ncbi.nlm.nih.gov/pubmed/19145403>
- 30 Kim SH, Kim W, Li XF, et al. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. *Arch Neurol* 2011; 68(11):1412-20. <http://jamanetwork.com/journals/jamaneurology/fullarticle/1107915>
- 31 Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. *N Engl J Med* 1998; 339:1217-27. <http://www.nejm.org/doi/full/10.1056/NEJM199810223391707>
- 32 Badalamenti MA, Hurst LC. Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren's contracture. *J Hand Surg Am* 2007; 32(6):767-74. <https://www.ncbi.nlm.nih.gov/pubmed/17606053>
- 33 Wetter TC. Restless legs syndrome: a review for the renal care professionals. *EDNA ERCA J* 2001; 27(1):42-6. <https://www.ncbi.nlm.nih.gov/pubmed/12603074>
- 34 Schaefer RM, Tylki-Szymańska A, Hilz MJ. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. *Drugs* 2009; 69(16):2179-205. <https://www.ncbi.nlm.nih.gov/pubmed/19852524>
- 35 Narváez J, Domingo-Domenech E, Gómez-Vaquero C, et al. Biological agents in the management of Felty's syndrome: a systematic review. *Semin Arthritis Rheum* 2012; 41(5):658-68. <https://www.ncbi.nlm.nih.gov/pubmed/22119104>
- 36 Weinschenker BG. Neuromyelitis optica: what it is and what it might be. *Lancet* 2003; 361(9361):889-90. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(03\)12784-5/abstract](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)12784-5/abstract)
- 37 Losacco T, Punzo C, Santacroce L. [Gardner syndrome: clinical and epidemiologic up to date]. *Clin Ter* 2005; 156(6):267-71. <https://www.ncbi.nlm.nih.gov/pubmed/16463563>
- 38 Okai T, Yamaguchi Y, Sakai J, et al. Case report: complete regression of colonic adenomas after treatment with sulindac in Gardner's syndrome: a 4-year follow-up. *J Gastroenterol* 2001; 36:778-82. <https://www.ncbi.nlm.nih.gov/pubmed/11757751>
- 39 Mignot E. Narcolepsy and the HLA system. *N Engl J Med* 2001; 344:692. <http://www.nejm.org/doi/full/10.1056/NEJM200103013440918#t=article>
- 40 Freeman RD, Zinner SH, Müller-Vahl KR, et al. Coprophenomena in Tourette syndrome. *Dev Med Child Neurol* 2009; 51(3):218-27. <https://www.ncbi.nlm.nih.gov/pubmed/19183216>
- 41 Turtle L, Robertson MM. Tics, twitches, tales: the experiences of Gilles de la Tourette's syndrome. *Am J Orthopsychiatry* 2008; 78(4):449-55. <https://www.ncbi.nlm.nih.gov/pubmed/19123766>
- 42 Himle MB, Woods DW, Piacentini JC, et al. Brief review of habit reversal training for Tourette syndrome. *J Child Neurol* 2006; 21(8):719-25. <https://www.ncbi.nlm.nih.gov/pubmed/16970874>
- 43 Hughes RA, Swan AV, Raphaël JC, et al. Immunotherapy for Guillain-Barré syndrome: a systematic review. *Brain* 2007; 130(Pt 9):2245-57. <https://www.ncbi.nlm.nih.gov/pubmed/17337484>
- 44 Nagayama H, Katayama Y, Nippon Rinsho. [Apheresis therapy in Guillain-Barré syndrome]. *Nihon Rinsho* 2008; 66(6):1195-9. <https://www.ncbi.nlm.nih.gov/pubmed/18540370>



- 45 McCusker EJ, Richards F, Silience D, *et al.* Huntington's disease: neurological assessment of potential gene carriers presenting for predictive DNA testing. *Clin Neurosci* 2000; 7(1):38-41. <https://www.ncbi.nlm.nih.gov/pubmed/10847649>
- 46 Tranebjærg L, Samson RA, Green GE. Jervell and Lange-Nielsen Syndrome. *GeneReviews*® 2002 July 29 [updated November 2014]. <https://www.ncbi.nlm.nih.gov/books/NBK1405/>
- 47 Bersudsky M, Rosenberg P, Rudensky B, *et al.* Lipopolysaccharides of a *Campylobacter coli* isolate from a patient with Guillain-Barré syndrome display ganglioside mimicry. *Neuromuscul Disord* 2000; 10:182-6. <https://www.ncbi.nlm.nih.gov/pubmed/10734265>
- 48 Janniger CK. Klippel-Trenaunay-Weber syndrome. *Medscape*. 2016. <http://reference.medscape.com/article/1084257-overview>
- 49 Vassalo R, Ryu JH, Colby TV, *et al.* Pulmonary Langerhans cell histiocytosis. *N Engl J Med* 2000 342:1969-78. <http://www.nejm.org/doi/full/10.1056/NEJM200006293422607>
- 50 Beyerbach DM. Lown-Ganong-Levine syndrome. *Medscape*. 2015. <http://emedicine.medscape.com/article/160097-overview>
- 51 Quinlivan R, Vissing J, Hilton-Jones D, *et al.* Physical training for McArdle disease. *Cochrane Database Syst Rev* 2011; 12:CD007931. <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007931.pub2/abstract>
- 52 Quinlivan R, Martinuzzi A, Schoser B. Pharmacological and nutritional treatment for McArdle disease (glycogen storage disease type V). *Cochrane Database Syst Rev* 2010; 12:CD003458. <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003458.pub4/abstract>
- 53 Ault J. Marchiafava-Bignami disease. *Medscape*. 2016. <http://emedicine.medscape.com/article/1146086-overview>
- 54 Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. *Lancet* 2009; 373(9665):759-67. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(09\)60001-5/abstract](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)60001-5/abstract)
- 55 Lambrecht NW. Ménétrier's disease of the stomach: a clinical challenge. *Curr Gastroenterol Rep* 2011; 13(6):513-17. <https://www.ncbi.nlm.nih.gov/pubmed/21931998>
- 56 Yamamoto M, Harada S, Ohara M, *et al.* Clinical and pathological differences between Mikulicz's disease and Sjögren's syndrome. *Rheumatology (Oxford)* 2005; 44(2):227-34. <http://rheumatology.oxfordjournals.org/content/44/2/227.long>
- 57 Asher RAJ. Munchausen's syndrome. *Lancet* 1951; 257:339-41. <https://www.ncbi.nlm.nih.gov/pubmed/14805062>
- 58 Ponc R, Saunders MD, Kimmey MB. Neostigmine for the treatment of acute colonic pseudo-obstruction. *N Engl J Med* 1999; 341:137-41. <http://www.nejm.org/doi/full/10.1056/NEJM199907153410301#t=article>
- 59 Hatzimouratidis K, Eardley I, Giuliano F, *et al.* EAU guidelines on penile curvature. *Eur Urol* 2012; 62(3):543-52. <https://www.ncbi.nlm.nih.gov/pubmed/22658761>
- 60 Kim ED. Local therapies to heal the penis: fact or fiction? *J Androl* 2008; 30(4):384-90. <https://www.ncbi.nlm.nih.gov/pubmed/19023141>
- 61 Omar Millán IF, Candel Erenas JM, *et al.* [Up-date of the diagnosis and treatment of vasospastic angina]. *Rev Clin Esp* 2008; 208(2):94-6. <https://www.ncbi.nlm.nih.gov/pubmed/18261397>
- 62 Keller KB, Lemberg L. Prinzmetal's angina. *Am J Crit Care* 2004; 13(4):350-4. <https://www.ncbi.nlm.nih.gov/pubmed/15293589>
- 63 Wanders RJA, Waterham HR, Leroy BP. Refsum disease. *GeneReviews*® 2006 March 20 [updated June 11 2015]. <https://www.ncbi.nlm.nih.gov/books/NBK1353/>
- 64 Fox RI. Sjögren's syndrome. *Lancet* 2005; 366:321-31. <https://www.ncbi.nlm.nih.gov/pubmed/1603937>
- 65 Worswick S, Cotliar J. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options. *Dermatol Ther* 2011; 24(2):207-18. <https://www.ncbi.nlm.nih.gov/pubmed/21410610>
- 66 Jayne DRW. Conventional treatment and outcome of Wegener's granulomatosis and microscopic polyangiitis. *CCJM* 2002; 69(Suppl 2):S1110-5. <http://www.ccjm.org/supplements/single-view/conventional-treatment-and-outcome-of-wegener-s-granulomatosis-and-microscopic-polyangiitis/Od8061df0951aa4829194e88a0a1ba6b.html>
- 67 Kuo SH, Debnam JM, Fuller GN, *et al.* Wernicke's encephalopathy: an underrecognized and reversible cause of confusional state in cancer patients. *J Oncology* 2009; 76(1):10-8. <https://www.karger.com/Article/Abstract/174951>
- 68 Marth T, Raoult D. Whipple's disease. *Lancet* 2003; 361(9353):239-46. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(03\)12274-X/abstract](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)12274-X/abstract)
- 69 Auernhammer CJ, Göke B. Medical treatment of gastrinomas. *Wien Klin Wochenschr* 2007; 119(19-20):609-15. <https://www.ncbi.nlm.nih.gov/pubmed/17985097>
- 70 Anon. Listening to patients with rare diseases. *Lancet* 2009; 373:868. [http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736\(09\)60519-5.pdf](http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(09)60519-5.pdf)

## Chapter 16: Radiology

No references for this chapter

## Chapter 17: Reference intervals

No references for this chapter

## Chapter 18: Practical procedures

- 1 Johnston AJ, Streater CT, Noorani R, *et al.* The effect of peripherally inserted central catheter (PICC) valve technology on catheter occlusion rates - The 'ELeCTRiC' study. *J Vasc Access* 2012; 13(4):421-5. <https://www.ncbi.nlm.nih.gov/pubmed/22505280>



- 1 Hawkes C. Smart handles and red flags in neurological diagnosis. *Hosp Med* 2002; 63:732-42. <https://www.ncbi.nlm.nih.gov/pubmed/12512200>
- 2 NICE. *Sepsis: Recognition, diagnosis and early management* [NG51]. 2016. <https://www.nice.org.uk/guidance/ng51>
- 3 Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J* 2012; 33(20):2569-619. <http://eurheartj.oxfordjournals.org/content/33/20/2569.long>
- 4 Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J* 2016; 37(3):267-315. <http://eurheartj.oxfordjournals.org/content/37/3/267.long>
- 5 NICE. *Ticagrelor for the treatment of acute coronary syndromes* [TA236]. 2011. <https://www.nice.org.uk/guidance/ta236>
- 6 Resuscitation Council (UK). *Advanced life support* (7th edn). London: Resuscitation Council (UK), 2016
- 7 Scottish Intercollegiate Guidelines Network. *British guideline on the management of asthma* (SIGN 141). 2014. <https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2014/>
- 8 NICE. Management of exacerbations of COPD. In: *Chronic obstructive pulmonary disease in over 16s: Diagnosis and management* [CG101]. 2010. <https://www.nice.org.uk/guidance/cg101/chapter/1-guidance#management-of-exacerbations-of-copd>
- 9 MacDuff A, Arnold A, Harvey J, et al. Management of spontaneous pneumothorax: British Thoracic Society pleural disease guideline 2010. *Thorax* 2010; 65(Suppl 2):ii18-31. [http://thorax.bmj.com/content/65/Suppl\\_2/ii18.long](http://thorax.bmj.com/content/65/Suppl_2/ii18.long)
- 10 Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. *Thorax* 2009; 64(Suppl 3):iii1-55. [http://thorax.bmj.com/content/64/Suppl\\_3/iii1.long](http://thorax.bmj.com/content/64/Suppl_3/iii1.long)
- 11 NICE. Recommendations. In: *Venous thromboembolic diseases: Diagnosis, management and thrombophilia testing* [CG141]. 2012. <https://www.nice.org.uk/guidance/cg144/chapter/recommendations>
- 12 NICE. *Acute upper gastrointestinal bleeding in over 16s: Management* [CG141]. 2012. <https://www.nice.org.uk/guidance/cg141>
- 13 McGill F, Heyderman R, Michael B, et al. The UK Joint Specialist Societies guideline on the diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent adults. *J Infect* 2016; 72:405-38. [http://www.journalofinfection.com/article/S0163-4453\(16\)00024-4/abstract](http://www.journalofinfection.com/article/S0163-4453(16)00024-4/abstract)
- 14 NICE. *Epilepsies: Diagnosis and management* [CG137]. 2012, updated 2016. <https://www.nice.org.uk/guidance/cg137>
- 15 NICE. *Head injury: Assessment and early management* [CG176]. 2014. <https://www.nice.org.uk/guidance/cg176>
- 16 Joint British Diabetes Societies Inpatient Care Group. *The management of diabetic ketoacidosis in adults*. Second edition. Update: September 2013. <https://www.diabetes.org.uk/Documents/About%20Us/What%20we%20say/Management-of-DKA-241013.pdf>
- 17 Joint British Diabetes Societies Inpatient Care Group. *The management of the hyperosmolar hyperglycaemic state (HHS) in adults with diabetes*. August 2012. <https://www.diabetes.org.uk/Documents/Position%20statements/JBDS-IP-HHS-Adults.pdf>